Has Richard Manes, MD received payments from drug or device companies?

Yes. Drug and device makers reported $66,940 in general payments to Richard Manes, MD across 96 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Richard Manes, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Richard Manes, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Richard Manes, MD

Otolaryngology · New Haven, CTNPI 1104077650

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $48,655 of the $66,940 with a category attached, or 72.7%. Neurent Medical Limited accounts for 89.8% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $53,898, more than ten times the $586 reported in 2019. Among otolaryngology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$66,940in general payments, 2019–2025

Across 96 payments — averaging $697.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Neurent Medical Limited$60K
Medtronic$2K
Spirair, Inc.$2K
Sanofi$1K
Integra Lifesciences Corporation$958
Intersect ENT, Inc.$391
plus $708 from 6 others

$179,068in research payments, 2019–2025

Across 98 payments — averaging $1827.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Optinose US, Inc.$115K
GSK$56K
Intersect ENT, Inc.$4K
Paratek Pharmaceuticals, Inc.$4K

What the payments were for

Consulting fees$48,65573%
Travel & lodging$13,81921%
Food & beverage$4,4667%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Neurent Medical Limited	42	$60,131
Medtronic(2 entities)	15	$1,704
Spirair, Inc.	2	$1,607
Sanofi	5	$1,441
Integra Lifesciences Corporation	9	$958
Intersect ENT, Inc.	3	$391
Regeneron Healthcare Solutions, Inc.	9	$272
Aerin Medical Inc.	2	$125
Stryker	2	$111
GSK	5	$95
Optinose US, Inc.	1	$83
Acclarent, Inc	1	$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

NEUROMARK Radiofrequency Console$59,498
NEUROMARK System$50,004
NEUROMARK Device$9,493
SeptAlign$3,215
TURBALIGN$3,215
DUPIXENT$1,387
INTEGRA$1,219
HYDRODEBRIDER$563
INTEGRA DERMAL REGENERATION TEMPLATE$406
PRIMATRIX$406
Acclarent Aera$384
Inspira Air$384
TruDi Probe$384
SINUVA$374
RELIEVA SPINPLUS NAV$278
PROPEL$242
STEALTHSTATION S8 PLATFORM$165
VIVAER STYLUS$106
RHINAER STYLUS$106

How this compares

$66,940 in reported general payments places this provider in the 95th percentile of 119 otolaryngology providers in Connecticut.

See all otolaryngology providers in Connecticut →

Medicare billing

Part B allowed, 2024

$95,850

Medicare patients

151

Services billed

459

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Dupixent PenDupilumab	65	$237,559
Azelastine Hcl	62	$1,827
Ipratropium Bromide	96	$1,544
Fluticasone Propionate	62	$1,426
Mupirocin	37	$191
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav	15	$169
Montelukast Sodium	41	$155
Prednisone	23	$95
Esomeprazole Magnesium	12	$95
Levocetirizine Dihydrochloride	17	$60

Paid to pharmacies, not to this prescriber.

Other otolaryngology in New Haven

Sara PaiNew Haven$160K
Howard BoeyNew Haven$19K
Wendell YarbroughNew Haven$6K
Ken YanagisawaNew Haven$5K
Mark DagostinoNew Haven$5K
Clarence SasakiNew Haven$5K
Eaton ChenNew Haven$4K
Tiffany ChenNew Haven$3K
Catherine BrophyNew Haven$3K
Paul FortgangNew Haven$3K

See the full list for Connecticut →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →